FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159885083> ?p ?o ?g. }

• W2159885083 endingPage "1712" @default.
• W2159885083 startingPage "1706" @default.
• W2159885083 abstract "Purpose A recent report of the combination of gemcitabine and docetaxel described favorable results in patients with uterine leiomyosarcoma. The objective of this report is to describe experience with this combination in a variety of histologic subtypes of sarcoma. Additionally, cell-culture studies were performed to assess the effect of the sequence of drug administration on colony formation. Patients and Methods A medical record review of 35 patients receiving the gemcitabine/docetaxel combination was undertaken. Gemcitabine 675 mg/m 2 intravenously was administered over 90 minutes on days 1 and 8, and docetaxel 100 mg/m 2 intravenously was administered over 60 minutes on day 8 of a 21-day cycle. Cell culture studies using the SAOS-2 osteosarcoma cell line and MCF-7 breast cancer cell line were also performed. Gemcitabine and docetaxel were added to cells either simultaneously for 24 hours, gemcitabine for 24 hours followed by docetaxel for 24 hours, or the reverse sequence. Results Thirty-five patients were treated. Five complete responses and 10 partial responses were observed for an overall response rate of 43%. Responses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma. In the cell culture studies, gemcitabine followed by docetaxel provided synergy. In contrast, the administration of drugs simultaneously resulted in antagonism, and docetaxel followed by gemcitabine provided mixed results. Conclusion The combination of gemcitabine and docetaxel seems to be active in a variety of sarcomas. A multicenter, randomized clinical trial in soft tissue sarcoma comparing gemcitabine alone with this combination, is ongoing." @default.
• W2159885083 created "2016-06-24" @default.
• W2159885083 creator A5011595369 @default.
• W2159885083 creator A5035822419 @default.
• W2159885083 creator A5036814863 @default.
• W2159885083 creator A5043549832 @default.
• W2159885083 creator A5053910810 @default.
• W2159885083 creator A5061209536 @default.
• W2159885083 creator A5077232908 @default.
• W2159885083 creator A5086016385 @default.
• W2159885083 creator A5087313131 @default.
• W2159885083 creator A5088763033 @default.
• W2159885083 date "2004-05-01" @default.
• W2159885083 modified "2023-10-17" @default.
• W2159885083 title "Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma" @default.
• W2159885083 cites W1520702439 @default.
• W2159885083 cites W1882650898 @default.
• W2159885083 cites W1892579032 @default.
• W2159885083 cites W1908664989 @default.
• W2159885083 cites W1917401325 @default.
• W2159885083 cites W1939916640 @default.
• W2159885083 cites W1968785826 @default.
• W2159885083 cites W1975828433 @default.
• W2159885083 cites W1981483088 @default.
• W2159885083 cites W2003743385 @default.
• W2159885083 cites W2007640889 @default.
• W2159885083 cites W2045371413 @default.
• W2159885083 cites W2070871717 @default.
• W2159885083 cites W2087581153 @default.
• W2159885083 cites W2089062211 @default.
• W2159885083 cites W2109694492 @default.
• W2159885083 cites W2139248078 @default.
• W2159885083 cites W2161170571 @default.
• W2159885083 cites W2161378536 @default.
• W2159885083 cites W2166797470 @default.
• W2159885083 cites W2168902572 @default.
• W2159885083 cites W2177569300 @default.
• W2159885083 cites W2268003579 @default.
• W2159885083 cites W2275599683 @default.
• W2159885083 cites W2402632476 @default.
• W2159885083 cites W26253050 @default.
• W2159885083 cites W4293241248 @default.
• W2159885083 doi "https://doi.org/10.1200/jco.2004.08.043" @default.
• W2159885083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15117993" @default.
• W2159885083 hasPublicationYear "2004" @default.
• W2159885083 type Work @default.
• W2159885083 sameAs 2159885083 @default.
• W2159885083 citedByCount "216" @default.
• W2159885083 countsByYear W21598850832012 @default.
• W2159885083 countsByYear W21598850832013 @default.
• W2159885083 countsByYear W21598850832014 @default.
• W2159885083 countsByYear W21598850832015 @default.
• W2159885083 countsByYear W21598850832016 @default.
• W2159885083 countsByYear W21598850832017 @default.
• W2159885083 countsByYear W21598850832018 @default.
• W2159885083 countsByYear W21598850832019 @default.
• W2159885083 countsByYear W21598850832020 @default.
• W2159885083 countsByYear W21598850832021 @default.
• W2159885083 countsByYear W21598850832022 @default.
• W2159885083 countsByYear W21598850832023 @default.
• W2159885083 crossrefType "journal-article" @default.
• W2159885083 hasAuthorship W2159885083A5011595369 @default.
• W2159885083 hasAuthorship W2159885083A5035822419 @default.
• W2159885083 hasAuthorship W2159885083A5036814863 @default.
• W2159885083 hasAuthorship W2159885083A5043549832 @default.
• W2159885083 hasAuthorship W2159885083A5053910810 @default.
• W2159885083 hasAuthorship W2159885083A5061209536 @default.
• W2159885083 hasAuthorship W2159885083A5077232908 @default.
• W2159885083 hasAuthorship W2159885083A5086016385 @default.
• W2159885083 hasAuthorship W2159885083A5087313131 @default.
• W2159885083 hasAuthorship W2159885083A5088763033 @default.
• W2159885083 hasBestOaLocation W21598850831 @default.
• W2159885083 hasConcept C126322002 @default.
• W2159885083 hasConcept C141071460 @default.
• W2159885083 hasConcept C142724271 @default.
• W2159885083 hasConcept C143998085 @default.
• W2159885083 hasConcept C2776694085 @default.
• W2159885083 hasConcept C2777532014 @default.
• W2159885083 hasConcept C2778256501 @default.
• W2159885083 hasConcept C2778629024 @default.
• W2159885083 hasConcept C2780258809 @default.
• W2159885083 hasConcept C2781190966 @default.
• W2159885083 hasConcept C71924100 @default.
• W2159885083 hasConceptScore W2159885083C126322002 @default.
• W2159885083 hasConceptScore W2159885083C141071460 @default.
• W2159885083 hasConceptScore W2159885083C142724271 @default.
• W2159885083 hasConceptScore W2159885083C143998085 @default.
• W2159885083 hasConceptScore W2159885083C2776694085 @default.
• W2159885083 hasConceptScore W2159885083C2777532014 @default.
• W2159885083 hasConceptScore W2159885083C2778256501 @default.
• W2159885083 hasConceptScore W2159885083C2778629024 @default.
• W2159885083 hasConceptScore W2159885083C2780258809 @default.
• W2159885083 hasConceptScore W2159885083C2781190966 @default.
• W2159885083 hasConceptScore W2159885083C71924100 @default.
• W2159885083 hasIssue "9" @default.
• W2159885083 hasLocation W21598850831 @default.
• W2159885083 hasLocation W21598850832 @default.
• W2159885083 hasOpenAccess W2159885083 @default.

• next